Synthesis, QSAR, and molecular dynamics simulation of amidino-substituted benzimidazoles as dipeptidyl peptidase III inhibitors by Rastija, Vesna et al.
867Acta Chim. Slov. 2015, 62, 867–878
Rastija et al.:  Synthesis, QSAR, and molecular dynamics simulation   ...
Scientific paper
Synthesis, QSAR, and Molecular Dynamics Simulation 
of Amidino-substituted Benzimidazoles as Dipeptidyl 
Peptidase III Inhibitors
Vesna Rastija,1,* Dejan Agi},1 Sanja Tomi},2 Sonja Nikoli},2 Marijana Hranjec,3
Grace Karminski-Zamola3 and Marija Abrami}2
1 Josip Juraj Strossmayer University of Osijek, Faculty of Agriculture in Osijek, Petra Sva~i}a 1d, 31 000 Osijek, Croatia  
2 The Ru|er Bo{kovi} Institute, P.O. Box 180, Zagreb, 10 002, Croatia 
3 University of Zagreb, Faculty of Chemical Engineering and Technology, P.O. Box 177, Zagreb, 10 000, Croatia 
* Corresponding author: E-mail: vrastija@pfos.hr. 
Phone: +385 31 554 903 (V. Rastija).
Received: 09-04-2015
Abstract
A molecular modeling study has been performed on a series of 16 benzimidazole-based inhibitors of human dipeptidyl
peptidase III (DPP III). Eight of these were novel compounds synthesized in excellent yields using green chemistry ap-
proach. This study aims at elucidating the structural features of benzimidazole derivatives required for the antagonism
of human DPP III activity using Quantitative Structure-Activity Relationship (QSAR) analysis, and at understanding
the mechanism of one of the most potent inhibitor bindings into the active site of this enzyme, namely by molecular
dynamics (MD) simulations. The best model obtained includes S3K and RDF045m descriptors, which have explained
89.4% of inhibitory activity. The depicted moiety for the strong inhibition activity matches the structure of the most po-
tent compound. MD simulation has revealed the importance of imidazolinyl and phenyl groups in the mechanism of bin-
ding into the active site of human DPP III.
Keywords: Molecular modeling; dipeptidyl peptidase III; benzimidazole derivatives 
1. Introduction
Dipeptidyl peptidases (DPPs) are a subclass of exo-
peptidases including enzymes that cleave two amino acids
from the amino-end of a peptide chain. Dipeptidyl pepti-
dasese III (DPP III; EC 3.4.14.4) is the sole member of the
M49 family of metallopeptidases.1 DPP III sequentially
hydrolyses dipeptides from the N-terminal of various
oligopeptides, but has restricted specificity on dipeptidyl
arylamide substrates, preferring Arg-Arg-2-naphthylami-
de. The ligand-free crystal structure of yeast DPP III has
revealed the unique protein fold and zinc-binding site, en-
abling an insight into the possible catalytic mechanism.2
DPP III from Saccharomyces cerevisiae has a two-lobe
structure with a wide cleft through the middle containing
the catalytic zinc ion, which is the possible substrate-bin-
ding site. The recently resolved crystal structure of human
DPP III (PDB ID: 3FVY)3 shows close resemblance to the
yeast DPP III (PDB ID: 3CSK).2 DPP III has been im-
plicated in intracellular protein catabolism, oxidative
stress response,4 and various physiological processes,
such as blood pressure and pain regulation mechanism,5,6
related to the hydrolysis of bioactive peptides,1 as well as
in some pathological processes – the cataractogenesis7
and progression of ovarian cancer.8 Due to its biological
significance, human DPP III is interesting as a potential
drug target. Specific inhibitors have proven important for
determining the mechanism of action and the physiologi-
cal role of several mammalian metallopeptidases.9 Howe-
ver, efforts are still rarely invested in designing and
synthesizing the specific inhibitors of DPP III. It is known
that inhibition by non-specific chelating and thiol reagents
is a feature of DPP III originating from various species,
and that opioid pentapeptide tynorphin is a potent inhibi-
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tor of DPP III isolated from the monkey brain.10 In addi-
tion, synthetic hemorphin-like pentapeptides have been
shown to possess strong inhibitory activity towards the re-
combinant rat DPP III.11 Since it has been reported that
the peptidic inhibitors of DPP III are degraded in the hu-
man body by (amino) peptidases,10,12 we have investigated
a series of benzimidazole derivatives in order to find new
and more potent non-peptidic inhibitors of human DPP
III.13
To improve the inhibitory potency, a cyclobutane
ring was included in the structure of diamidino-substi-
tuted dibenzimidazole. A structural feature important for
the enhanced inhibitory activity of these compounds see-
med to be the presence of cyclized amidino group coupled
to benzimidazole moiety and the presence of an additional
aromatic ring.13
Since the benzimidazole derivatives investigated in
our previous study showed wide variation in their structu-
res, our present study aims at elucidating the structural
features of benzimidazole derivatives required for the an-
tagonism of dipeptidyl peptidase III using the Quantitati-
ve Structure-Activity Relationship (QSAR) analysis. In
order to understand the mechanism of the most potent in-
hibitor binding into the active site of human DPP III, we
have performed molecular dynamic simulation.
2. Experiment
2. 1. General Method for Preparing 
Compounds 1–16
A solution (c = 1.3 × 10–2 M) of corresponding E-2-
styryl-5(6)-N-amidino-substituted-benzimidazole
hydrochlorides or E-N-substituted-2-(2-thiophen/furyl-2-
yl-vinyl)-3H-benzimidazole-5(6)-carboxamidine
hydrochlorides in water was irradiated at room temperatu-
re with a 400 W high-pressure mercury lamp using a
Pyrex filter for 2 h. The air was bubbled through the solu-
tion. The solution was concentrated, precipitated with
acetone, and the resulting solid was filtered off. The pro-
duct was dissolved in ethanol and precipitated with di-
ethyl-ether, filtered off, and dried. The procedure was re-
peated two times until the product was analytically pure.
The synthesis of compounds 1-2, 4-6, 8-9 and 13 had been
previously published.13
The obtained cyclobutane derivatives are of the
head-to-tail type, which was confirmed by mass spectro-
metry, namely by the presence of the same m/z fragment
ion in mass spectrometry. 
Melting points were determined on a Koffler hot-
stage microscope and are uncorrected. IR spectra were re-
corded on the Nicolet magna 760, Perkin-Elmer 297, and
Perkin-Elmer Spectrum 1 spectrophotometers, with KBr
disks. 1H and 13C NMR spectra were recorded on the Va-
rian Gemini 300, Bruker Avance DPX 300, and Bruker
Avance DRX 500 spectrometers using TMS as an internal
standard in DMSO-d6. Mass spectra were recorded on the
Agilent 1100 series LC/MSD Trap SL. Elemental analy-
ses for carbon, hydrogen, and nitrogen were performed on
a Perkin-Elmer 2400 elemental analyzer and a Perkin-El-
mer, Series II, CHNS Analyzer 2400. Where analyses are
indicated only as symbols of elements, analytical results
obtained are within 0.4% of the theoretical value. In pre-
parative photochemical experiments, irradiation was per-
formed at room temperature with a water-cooled immer-
sion well and an “Origin Hanau” 400-W high-pressure
mercury arc lamp, using Pyrex glass as a filter. 
All 2-benzimidazolyl-substituted cyclobutane deri-
vatives 1-16 were synthesized according to Scheme 1 by
reaction of photochemical [2+2] cycloaddition in water,
starting from the corresponding, previously prepared 2-
styrylbenzimidazoles.
Scheme 1. Synthetic procedure of a series of benzimidazole deri-
vatives.
The corresponding N-amidino-substituted E-2-
styryl-1H-benzimidazoles and E-N-substituted-2-(2-
thiophen/furyl-2-yl-vinyl)-3H-benzimidazole-5(6)-carbo-
xamidines were prepared by the condensation reaction of
o-substituted-3-phenyl-propenales or 3-thiophen(furan)-
2-yl-propenales with 4-N-amidino-substituted 1,2-pheny-
lenediamines and p-benzoquinone.14,15 Cyclobutane deri-
vatives appeared as a constant reaction mixture containing
869Acta Chim. Slov. 2015, 62, 867–878
Rastija et al.:  Synthesis, QSAR, and molecular dynamics simulation   ...
two stereoisomers, with a very high amount of one isomer
(> 98%). The mixture of isomers could not be separated
either by column chromatography or by the HPLC/MS
method. According to the mass spectra, which showed
small molecular ion and high base peaks m/z M+/2, we as-
signed them as head-to-tail adducts. The 1H and 13C NMR
data confirmed the symmetrical cyclobutane structure.
The direct elucidation of cyclobutane ring stereochemi-
stry was very difficult due to the highly overlapped aryl
and benzimidazole signals in 1H NMR spectra. In compa-
rison to the starting benzimidazole derivatives, the 1H
NMR spectra of cyclobutane derivatives showed the di-
sappearance of signals related to the trans-ethylenic doub-
le bond, with the coupling constants of 16 Hz, while two
signals for four cyclobutane protons appeared in the alip-
hatic part of the spectra in 1:1 ratio, which confirmed their
symmetrical structure. The 2D NOESY NMR spectra, as
well as HETCOR, confirmed the suggested stereochemi-
stry of cyclobutane derivatives due to the NOE interac-
tions between cyclobutane protons and the NH of benzi-
midazole nuclei, as well as those between cyclobutane
protons and aryl protons.
1,3-di-[5(6)-(N-4-morpholinylamidino)2-benzimida-
zolyl]-2,4-di-phenylcyclobutane dihydrochloride (3) was
prepared using the above-described method from E-N-
Morpholin-4-yl-2-styryl-3H-benzimidazole-5(6)-carbo-
xamidine hydrochloride (0.15 g; 0.39 mmol) after 2 hours
of irradiation. 0.114g (76%) of yellow powder obtained;
mp = 259–261 °C. 
MS m/z: 695 (M+1(-2HCl) 25%), 263 (M+2/2,
100%); 1H NMR (DMSO-d6) (δ /ppm) 13.20–13.09 (m,
2H, NHbenzimid.), 11.20 (s, 2H, NHamid.), 9.65 (s, 2H,
NHamid.), 9.02 (brs, 2H, NHamid.), 7.86 (s, 2H, Harom.),
7.81(d, 2H, J = 8.70 Hz, Harom.), 7.68 (d, 2H, J = 8.66 Hz,
Harom.), 7.64 (dd, 4H, J1 = 7.86 Hz, J2 = 1.46 Hz, Harom.),
7.43–7.28 (m, 6H, Harom.), 5.46 (d, 2H, J2 = 7.88 Hz, H
cyclobut.), 5.19 (d, 2H, J2 = 7.94 Hz, H cyclobut.); 
13C NMR
(DMSO-d6) (δ /ppm): 162.23 (2C), 156.74 (2C), 142.45
(2C), 139.10 (2C), 138.10 (2C), 130.01 (2C), 128.69
(2C), 127.85 (4C), 127.41 (2C), 126.33 (2C), 120.93
(2C), 118.36 (2C), 118.32 (2C), 65.49 (4C), 53.83 (4C),
44.37 (2C), 41.41 (2C); Anal. Calcd for
(C40H44Cl2N10O2): C 62.58, 5.78, N 18.24; Found: C
62.73, H 5.40, N 18.56.
1,3-di-[5(6)-(N-4-morpholinylamidino)2-benzimida-
zolyl]-2,4-di-2-chlorphenyl-cyclobutane dihydrochloride
(7) was prepared using the above-described method from
E-2-[2-(2-chloro-phenyl)-vinyl]-N-morpholin-4-yl-3H-
benzimidazole-5(6)-carboxamidine hydrochloride (0.15
g; 0.36 mmol) after 2 hours of irradiation. 0.112g (75%)
of light violet powder obtained; mp = 267–269 °C. MS
m/z: 763 (M+1(–2HCl) 30%), 383 (M+2/2, 100%); 1H
NMR (DMSO-d6) (δ /ppm) 13.20 (brs, 2H, NHbenzimid.),
11.24 (s, 2H, NHamid.), 9.80 (s, 2H, NHamid.), 9.10 (bs, 2H,
NHamid.), 7.93 (s, 2H, Harom.), 7.84(d, 2H, J = 8.64 Hz,
Harom.), 7.72 (d, 2H, J = 8.68 Hz, Harom.), 7.64 (t, 2H, J =
7.80 Hz, Harom.), 7.48–7.33 (m, 6H, Harom.), 5.20 (t, 2H, J =
7,15 Hz, H cyclobut.), 4.99 (t, 2H, J = 7,10 Hz, Hcyclobut.); 
13C
NMR (DMSO-d6) (δ /ppm): 162.78 (2C), 157.00 (2C),
142.74 (2C), 139.18 (2C), 138.22 (2C), 134.65 (2C),
130.07 (2C), 128.81 (2C), 127.89 (4C), 127.45 (2C),
126.36 (2C), 120.93 (2C), 118.65 (2C), 68.77 (4C), 63.89
(4C), 44.64 (2C), 41.77 (2C); Anal. Calcd for
(C40H42Cl4N10O2): C 57.40, 5.06, N 16.74; Found: C
57.65, H 5.38, N 6.51.
1,3-di-[5(6)-N-amidino-2-benzoimidazolyl]-2,4-di-(2-
furyl)cyclobutane dihydrochloride (10) was prepared us-
ing the above-described method from E-2-(2-furan-2-yl-
vinyl)-3H-benzimidazole-5-carboxamidine hydrochloride
(0.09 g; 0.31 mmol) after 2 hours of irradiation. 0.080g
(80%) of grey powder obtained; mp = >300 °C. MS m/z:
505 (M+1(–2HCl) 85%), 253 (M+2/2, 100%); 1H NMR
(DMSO-d6) (δ /ppm) 13.05 (brs, 2H, NHbenzimid.), 9.30
(brs, 8H, NHamid.), 8.17 (s, 2H, Harom.), 7.81 (d, 2H, J =
8.66 Hz, Harom.), 7.64 (d, 2H, J = 8.60 Hz, Harom.), 7.30 (d,
2H, J = 3.10 Hz, Hfuryl), 6.16 (d, 4H, J = 3.00 Hz, Hfuryl),
5.11 (t, 2H, J = 8.10 Hz, Hcyclobut.), 5.01 (t, 2H, J = 8.12
Hz, Hcyclobut.); 
13C NMR (DMSO-d6) (δ /ppm): 13C NMR
(DMSO-d6) (δ /ppm): 166.77 (2C), 156.17 (2C), 153.14
(2C), 142.99 (2C), 142.68 (2C), 138.94 (2C), 122.13
(2C), 120.85 (2C), 119.56 (2C), 112.25 (2C), 110.83
(2C), 107.52 (2C), 45.22 (2C), 40.79 (2C); Anal. Calcd
for (C28H26N8Cl2O2): C 58.24, H 4.54, N 19.40; Found: C
58.50, H 4.27, N 19.68.
1,3-di-[5(6)-N-isopropylamidino-2-benzoimidazolyl]-
2,4-di-(2-furyl)cyclobutane dihydrochloride (11) was
prepared using the above-described method from E-N-iso-
propyl-2-(2-furan-2-yl-vinyl)-3H-benzimidazole-5-car-
boxamidine hydrochloride (0.10 g; 0.30 mmol) after 2
hours of irradiation. 0.090g (90%) of grey powder obtai-
ned; mp = 274–276 °C. MS m/z: 589 (M+1(–2HCl) 15%),
253 (M+2/2, 100%); 1H NMR (DMSO-d6) (δ /ppm) 13.10
(brs, 2H, NHbenzimid.), 9.40 (brs, 4H, NHamid.), 9.10 (brs,
2H, NHamid.), 7.95 (s, 2H, Harom.), 7.76 (d, 2H, J = 8.60 Hz,
Harom.), 7.62 (d, 2H, J = 8.56 Hz, Harom.), 7.34 (d, 2H, J =
3.00 Hz, Hfuryl), 6.24 (d, 4H, J = 3.05 Hz, Hfuryl), 5.15 (t,
2H, J = 8.14 Hz, Hcyclobut.), 5.09 (t, 2H, J = 8.16 Hz, Hcyclo-
but.), 4.15–4.12 (m, 2H, CH), 1.27 (d, 12H, J = 6.26 Hz,
4CH3); 162.32 (2C), 155.72 (2C), 152.55 (2C), 142.28
(2C), 134.78 (2C), 122.24 (2C), 121.81 (2C), 120.99
(2C), 119.56 (2C), 110.41 (2C), 107.33 (2C), 107.19
(2C), 45.01 (2C), 40.78 (2C), 38.28 (2C), 21.33 (4C);
Anal. Calcd for (C34H38N8Cl2O2): C 61.72, H 5.79, N
16.94; Found: C 61.88, H 5.99, N 16.77.
1,3-di-[5(6)-N-cyclohexylamidino-2-benzoimidazolyl]-
2,4-di-(2-furyl)cyclobutane dihydrochloride (12) was
prepared using the above-described method from E-N-
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cyclohexyl-2-(2-furan-2-yl-vinyl)-3H-benzimidazole-5-
carboxamidine hydrochloride (0.100 g; 0.27 mmol) after
2 hours of irradiation. 0.070g (70%) of grey powder obtai-
ned; mp = 283–285 °C; MS m/z: 669 (M+1(–2HCl) 89%),
335 (M+2/2, 100%); 1H NMR (DMSO-d6) (δ /ppm) 13.20
(brs, 2H, NHbenzimid.), 9.62 (s, 2H, NHamid.), 9.49 (s, 2H,
NHamid.), 9.23 (s, 2H, NHamid.), 8.06 (s, 2H, Harom.), 7.80
(d, 2H, J = 8.40 Hz, Harom.), 7.67 (d, 2H, J = 8.90 Hz,
Harom.), 7.33 (s, 2H, Harom.), 6.40 (d, 2H, J = 3.10 Hz,
Hfuryl), 6.22 (d, 2H, J = 3.00 Hz, Hfuryl), 5.27 (t, 2H, J =
8.20 Hz, Hcyclobut.), 5.05 (t, 2H, J = 8.30 Hz, Hcyclobut.),
4.10–4.03 (m, 2H, CH), 1.99–1.70 (m, 10H, 5CH2);
1.59–1.40 (m, 10H, 5CH2); 
13C NMR (DMSO-d6) (δ
/ppm): 162.88 (2C), 155.16 (2C), 151.96 (2C), 151.27
(2C), 151.14 (2C), 143.15 (2C), 125.47 (2C), 124.71
(2C), 117.52 (2C), 113.09 (2C), 110.96 (2C), 108.52
(2C), 52.55 (2C), 40.36 (2C), 38.50 (2C), 31.55 (4C),
25.22 (2C), 23.50 (2C); Anal. Calcd for (C40H46N8Cl2O2):
C 64.77, H 6.25, N 15.11; Found: C 64.53, H 6.07, N
15.38.
1,3-di-[5(6)-N-4-morpholinylamidino-2-benzoimida-
zolyl]-2,4-di-(2-thienyl)cyclobutane dihydrochloride
(14) was prepared using the above-described method from
E-N-Morpholin-4-yl-2-(2-thiophen-2-yl-vinyl)-3H-benzi-
midazole-5(6)-carboxamidine hydrochloride (0.120 g;
0.31 mmol) after 3 hours of irradiation. 0.090 g (75%) of
grey powder obtained; mp = 271–274 °C. MS m/z: 707
(M+1(–2HCl) 15%), 354 (M+2/2, 100%); 1H NMR (DM-
SO-d6) (δ /ppm)
13.20 (brs, 2H, NHbenzimid.), 11.14 (bs, 2H, NHamid.),
9.67 (bs, 2H, NHamid.), 8.99 (bs, 2H, NHamid.), 8.14 (s, 2H,
Harom.), 7.72 (s, 2H, Harom.), 7.45 (d, 2H, J = 8.78 Hz,
Harom.), 7.21 (d, 2H, J = 5.00 Hz, Hthienyl), 7.11 (d, 2H, J =
8.72 Hz, Harom.), 6.81 (d, 2H, J = 5.04 Hz, Hthienyl), 5.25 (t,
2H, J = 7.80 Hz, Hcyclobut.), 4.78 (t, 2H, J = 7.80 Hz, Hcyclo-
but.), 3.78 (s, 8H, 4CH2), 2.95 (s, 8H, 4CH2); 
13C NMR
(DMSO-d6) (δ /ppm): 162.88 (2C), 156.00 (2C), 142.98
(2C), 142.19 (2C), 138.72 (2C), 134.37 (2C), 128.30
(2C), 127.30 (2C), 127.18 (2C), 119.74 (2C), 116.10
(2C), 113.90 (2C), 68.02 (4C), 54.34 (4C), 45.55 (2C),
42.80 (2C); Anal. Calcd for (C36H40N10Cl2S2O2): C 55.45,
H 5.17, N 17.96; Found: C 55.25, H 5.41, N 17.69.
1,3-di-[5(6)-N-isopropylamidino-2-benzoimidazolyl]-
2,4-di-(2-thienyl)cyclobutane dihydrochloride (15) was
prepared using the above-described method from E-N-iso-
propyl-2-(2-thiophen-2-yl-vinyl)-3H-benzimidazole-
5(6)-carboxamidine hydrochloride (0.135 g; 0.39 mmol)
after 3 hours of irradiation. 0.110 g (81%) of grey powder
obtained; mp = 273–276 °C. MS m/z: 621 (M+1(–2HCl)
10%), 311 (M+2/2, 100%); 1H NMR (DMSO-d6) (δ/ppm)
13.20 (brs, 2H, NHbenzimid.), 9.50 (brs, 4H, NHamid.), 9.02
(s, 2H, NHamid.), 8.03 (s, 2H, Harom.), 7.95 (d, 2H, J = 8.85
Hz, Harom.), 7.50 (d, 2H, J = 8.80 Hz, Harom.), 7.20 (d, 2H,
J = 5.20 Hz, Hthienyl), 7.10–6.79 (d, 2H, J = 4.80 Hz,
Hthienyl), 5.23 (t, 2H, J = 7.40 Hz, Hcyclobut.), 4.78 (t, 2H, J =
7.60 Hz, Hcyclobut.), 4.11–4.06 (m, 2H, CH), 1.30 (d, 12H, J
= 6.20 Hz, (CH3)2); 
13C NMR (DMSO-d6) (δ /ppm):
161.89 (2C), 155.78 (2C), 147.14 (2C), 142.34 (2C),
135.01 (2C), 127.99 (2C), 126.04 (2C), 125.34 (2C),
122.55 (2C), 119.71 (2C), 118.94 (2C), 112.06 (2C),
44.26 (2C), 30.42 (4C), 29.27 (4C); Anal. Calcd for
(C34H38N8Cl2S2): C 58.86, H 5.52, N 16.15; Found: C
58.60, H 5.26, N 16.38.
1,3-di-[5(6)-N-cyclohexylamidino-2-benzoimidazolyl]-
2,4-di-(2-thienyl)cyclobutane dihydrochloride (16) was
prepared using the above-described method from E-N-
cyclohexyl-2-(2-thiophen-2-yl-vinyl)-3H-benzimidazole-
5(6)-carboxamidine hydrochloride (0.100 g; 0.26 mmol)
after 3 hours of irradiation. 0.075 g (75%) of grey powder
obtained; mp = 261–264 °C. MS m/z: 669 (M+1(–2HCl)
75%), 335 (M+2/2, 100%); 1H NMR (DMSO-d6) (δ/ppm)
13.25 (brs, 2H, NHbenzimid.), 9.60 (brs, 4H, NHamid.), 9.16 (s,
2H, NHamid.), 8.06 (s, 2H, Harom.), 7.84 7.50 (d, 2H, J = 8.70
Hz, Harom.), 7.36 (d, 2H, J = 8.76 Hz, Harom.), 7.19 (d, 2H, J
= 4.95 Hz, Hthienyl), 6.80 (t, 2H, J = 4.80 Hz, Hthienyl), 5.23
(t, 2H, J = 7.80 Hz, Hcyclobut.), 4.76 (t, 2H, J = 7.70 Hz,
Hcyclobut.), 3.77–3.72 (m, 2H, CH), 1.94–1.75 (m, 10H,
5CH2), 1.60–1.51 (m, 10H, 5CH2); 
13C NMR (DMSO-d6)
(δ /ppm): 162.80 (2C), 155.77 (2C), 146.83 (2C), 142.19
(2C), 134.42 (2C), 127.90 (2C), 125.77 (2C), 125.30 (2C),
122.38 (2C), 119.59 (2C), 118.90 (2C), 111.96 (2C), 52.26
(2C), 45.60 (2C), 42.80 (2C), 31.64 (4C), 25.22 (2C),
24.76 (4C); Anal. Calcd for (C40H46N8Cl2S2): C 62.08, H
5.99, N 14.48; Found: C 62.37, H 6.21, N 14.67.
2. 2. Biochemical Methods
DPP III was purified to homogeneity from human
erythrocytes as described earlier.16 The inhibitory activity
of benzimidazole derivatives towards human DPP III was
assayed in 50 mM Tris-HCl buffer, pH 7.4. In brief, enzy-
me (2.7 nM) was incubated with an inhibitor (10 μM) for
10 min at 25 °C, followed by 5 min at 37 °C. The enzyma-
tic reaction was started with Arg-Arg-2NA (40 μM) as a
substrate, and after the 15 min incubation at 37 °C in a
water bath, the reaction was stopped and the absorbance
was measured using the spectrophotometric method des-
cribed above.17 The percentage of enzyme inhibition (%
inh.) was calculated by comparing the enzymatic activity
without (normal activity) and with an inhibitor (inhibited
activity), using the following formula:
% inh. = [(normal activity – inhibited 
activity) / (normal activity)] × 100% (1)
2. 3. Computational Methods
Quantitative Structure-Activity Relationship (QSAR)
analysis
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2. 3. 1. Descriptor Calculation
The 3D structure of 16 benzimidazole derivatives
(Table 1) were optimized applying the HyperChem 7.0
(HyperCube, Inc., Gainesville, FL), using the molecular
mechanics force field (MM+).18 Subsequently, all structu-
res were submitted to geometry optimization using the se-
mi-empirical AM1 method.19 Molecular structures were
optimized using the Polak-Ribiere algorithm until the root
mean square gradient was 0.1 kcal mol–1.
After geometry optimization, several physical and
chemical parameters were calculated with HyperChem:
the energy of the highest occupied molecular orbital (EHO-
MO), the energy of the lowest unoccupied molecular orbi-
tal (ELUMO), the difference between EHOMO and ELUMO
(GAP), the heat of formation (Hf), the hydration energy
(EHYDR), and the volume (V) of the molecule. The 2D and
3D molecular descriptors used in this study have been cal-
culated by applying the online software Parameter Client
(Virtual Computational Chemistry Laboratory,
http://146.107.217.178/lab/pclient/), an electronic remote
version of the Dragon program.20 These descriptors may
be grouped according to their dimensionality: 
1. Zero-dimensional (0D): constitutional descriptors;
2. One-dimensional (1D): charge, molecular des-
criptors;
3. Two-dimensional (2D): topological, topological
charge, 2D autocorrelation, BCUT, eigenvalue-
based, and E-state descriptors;
4. Three-dimensional (3D): randic molecular profi-
les, geometrical, RDF (Radial Distribution Func-
tion), Molecule Representation of Structures ba-
sed on Electron diffraction (3D-MoRSE), WHIM
(WeigHted Covariance Matrices), and GET-
AWAY (Geometry, Topology, and Atom Weights
AssemblY) descriptors.
2. 3. 2. Regression Analysis
The selection of descriptors based on the best-subset
method and the multiple regression analysis (MLR) was
performed with the use of STATISTICA 12 (StatSoft, Inc.
Tulsa, USA, 2013). The number of descriptors (I) in the
multiple regression equation was limited to two due to the
small number of compounds. The initial number of 1370
calculated molecular indices and physicochemical proper-
ties was reduced to 121 descriptors using the following
procedure:
The initial set of 1370 descriptors was divided into 7
groups. In every group, descriptors in which values were
degenerated were eliminated. A further selection of des-
criptors was performed by using the best-subset method.
The best-subset regression is a model-building technique
that finds the subset of predictor variables that best pre-
dicts the response on a dependent variable by linear re-
gression. The criterion for the best model is based on the
R2 values of the obtained models. The descriptor included
in the ten best two-variables and in the ten best one-va-
riable models was selected for further analysis. In the final
space of 121 selected descriptors, the best models were
found by using the best-subset method. 
The best models were selected based on the squared
correlation coefficient (R2), the adjusted standard devia-
tion of regression (S), and the Fisher ration values (F). In
order to avoid overfitting, the terminal selection of models
was based on an inter-correlation study between the va-
riables included in the equation. Models with highly inter-
correlated (|R| ≥ 0.70) descriptors were discarded.
2. 3. 3. Validation of QSAR Models
Models have been assessed by internal cross-valida-
tion, using the leave-one-out (LOO) method and Y-
scrambling, performed by QSARINS.21 The compound
number is insufficient for external validation. Internal va-
lidation included the following criteria: the coefficient of
determination (R2), adjusted (R2adj) coefficient, leave-one-
out coefficient (Q2LOO), the global correlation among the
descriptors (Kxx), the difference between the global corre-
lation between the molecular descriptors and y as the res-
ponse variable, the global correlation among the descrip-
tors (ΔK), and the Fisher ratio (F).
Internal validations also included the following para-
meters: root-mean-square error (RMSE); root-mean-square
error determined by using the cross-validated LOO method
(RMSEcv), the concordance correlation coefficient (CCC),
the LOO cross-validation (CCCcv), the mean absolute error
of the training set (MAE), the internal validation set
(MAEcv), and the predictive residual sum of squares determi-
ned by using the cross-validated LOO method (PRESScv).
The robustness of QSAR models was tested by
means of a Y-randomization test, where robust QSAR mo-
dels should have low R2yscr and low Q
2
yscr values.
22
2. 3. 4. Definition of the Applicability Domain 
of a Model
Investigation of the applicability domain of the pre-
diction model was performed by means of leverage plot
(plotting residuals vs. leverage of training compounds).
Detection of outliers was carried out for compounds that
had values of standardized residuals higher than two stan-
dard deviation units. The leverage h* of a compound is the
measure of its influence on the model and is defined as: 
h* = 3 × p’ / n (2)
where n is the number of training compounds and p’ is the
number of model-adjustable parameters.
2. 3. 4. 1. Dynamics simulations
The three-dimensional structure of ligand-free hu-
man dipeptidyl peptidase III was obtained from the
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Brookhaven Protein Databank23 (ID: 3FVY). The residues
of amino acids missing in the crystal structure of DPP III,
Pro224 – Asp227, were added using the program tleap, a
basic preparation program for Amber simulations availab-
le in the AMBER10 package (http://ambermd.org). In the
model, all Arg and Lys residues are positively charged
(+1) and all Glu and Asp residues are negatively charged
(–1), as expected in physiological (experimental) condi-
tions. The initial protonation of the protein was determi-
ned by the WHATIF-server (at pH 7.0; http://swift.cmbi.
ru.nl/servers/html/index.html) and the protonation of hi-
stidines was checked according to their ability to form
hydrogen bonds with the neighboring amino acid resi-
dues. Protein parametrization was performed within the
AMBER ff03 force field of Duan et al.,24 while the inhibi-
tor parameters were derived using the Antechamber in the
Amber10 program. For the zinc cation, Zn2+, parameters
were derived from previous work25 and modified accor-
ding to a PDB survey.26
The ligand-free DPP III and the protein-inhibitor
complex were placed in the truncated octahedron box fil-
led with TIP3P water molecules, and Na+ ions were ad-
ded in order to neutralize the systems. The resulting sys-
tem consisted of ∼ 80 700 atoms (∼ 69 000 atoms of wa-
ter). Electrostatic interactions were calculated using the
particle-mesh Ewald method. The same molecular dyna-
mics (MD) simulation procedure was used as in our previ-
ous publication.27 The structure of ligand-free DPP III ob-
tained after 30 ns of MD simulations was selected as a
starting point and a complex between the protein and the
inhibitor was built. Prior to the MD simulations of the
protein-inhibitor complex, protein geometry was optimi-
zed in four cycles with different constraints. In the first
(300 steps) and second (300 steps) cycles, water and the
inhibitor molecule were relaxed, while the protein and the
zinc atom were constrained using a harmonic potential
with a force constant of 133.98 kJ mol–1 Å–2. In the third
(300 steps) and fourth (300 steps) cycles, the same con-
stant was applied to the zinc atom while only the protein
backbone was constrained with 133.98 kJ mol–1 Å–2 and
41.87 kJ mol–1 Å–2, respectively. The energy minimization
procedure, consisting of 150 steps of steepest descent fol-
lowed by the conjugate gradient algorithm for the remai-
ning optimization steps, was the same in all four cycles.
During the first period of equilibration (200 ps of gentle
heating from 0 to 300 K), the NVT ensemble was used
while all of the following simulations (water density ad-
justment and productive simulations) were performed at a
constant temperature and pressure (300 K and 1 atm, the
NPT ensemble). The temperature was held constant using
the Langevin dynamics, with a collision frequency of 1
ps–1. Bonds involving hydrogen atoms were constrained
using the SHAKE algorithm. The complex was simulated
for 20 ns with a time step of 2 fs, and structures were sam-
pled every 1 ps. After 20 ns of MD simulation, in order to
enable a more efficient conformational space search, the
temperature of the protein-inhibitor complex was elevated
to 500 K, followed by its cooling back to 300 K. Both the
heating and cooling intervals were 300 ps long, and the ti-
me step was 1 fs. In between, the system was simulated
200 ps at 500 K. The rest of MD simulations (20 ns) were
carried out using the NPT ensemble and a time step of 2
fs. Altogether, MD simulations resulted in a 40.8 ns long
trajectory of the protein-inhibitor complex.
The radius of gyration (Rg), the root-mean square
deviation (RMSD), and the root-mean square coordinate
fluctuation (RMSF) of each residue in the system were
calculated using the »ptraj« module of the AMBER10
program.28,29
3. Results and Discussion
3. 1. Inhibitory Activity of Benzimidazole
Derivatives Towards Human DPP III 
Inhibitory activities of the analyzed compounds are
shown in Table 1. Fifteen of the sixteen analyzed com-
pounds at the concentration of 10 μM have shown inhibi-
tory effects against human DPP III. The strongest inhibi-
tion (% inh. > 90) has been obtained with compounds 1,
2, 5 and 9. A slightly lower inhibition has been observed
for the compounds 6, 8, 10 and 13, while others have
shown an inhibition of less than 30%. We have reported
earlier on that the inhibition of dipeptidyl peptidase IV
(DPP IV) has not detected in this type of benzimidazole
derivatives.13
Table 1. Inhibitory activities of benzimidazole derivatives against
human DPP III determined experimentally (% inh.exp), the calcula-
ted inhibitory activities (% inh.calc) obtained using model III, the re-
siduals, and the values of descriptors involved in the model.
Compound
S3K* RDF045m**
% % 
ResidualsNo. inh.exp
*** inh.calc
1 4.422 23.359 97.8 93.5 4.3
2 4.242 16.934 90.3 75.5 14.8
3 6.701 19.893 13.4 7.4 6.0
4 5.911 15.699 10.7 17.2 –6.5
5 4.801 29.106 97.2 102.7 –5.5
6 4.627 23.717 89.3 88.3 1.0
7 7.094 29.741 18.3 31.3 –13.0
8 6.304 30.541 69.4 59.7 9.7
9 4.003 15.225 94.2 76.8 17.4
10 3.8 15.537 67.6 84.5 –16.9
11 5.401 13.957 19.4 27.1 –7.7
12 6.245 18.962 14.7 18.6 –3.9
13 4.21 13.836 51.9 65.0 –13.1
14 6.446 19.952 0 15.8 –15.8
15 6.253 16.514 20.8 9.2 11.6
16 6.496 19.46 29.9 12.4 17.5
* S3K = topological descriptor, 3-path Kier alpha-modified shape in-
dex  ** RDF045m = RDF (Radial Distribution Function) group of
descriptors, *** at the 10 μmol L–1concentration of the compound
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3. 2. Results of the Multiple Regression
Analysis (MLR) 
To elucidate the structural features of the experi-
mentally examined benzimidazole derivatives required
for the antagonism of human DPP III activity, several
MLR models were built after the variable selection car-
ried out by the genetic algorithm. The models were ini-
tially developed by using the all-subset-procedure, until
two variable models achieved the best statistical parame-
ters. Considering the small data set of 16 compounds, 
it was not split into training and test. Models were vali-
dated by means of internal cross-validation (LOO) and
Y-scrambling. The best QSAR model with one descrip-
tor (I = 1) was:
Model I
% inh. = 84.031 (± 7.075) – 31.094 (± 6.592) N-067
The best two QSAR models with two descriptors
(I = 2) generated are:
Model II
% inh. = 243.246 (± 48.043) – 64.435 (± 16.863)
Mor24p – 6.725 (± 0.950) F08[C-N]
Model III
% inh. = 148.991 (± 17.812) – 32.159(± 3.170) S3K
+ 3.713(± 0.628) RDF045m
Statistical parameters of the obtained models are gi-
ven in Table 2.
A comparison of various statistical parameters given
in Table 2 reveals that the performance of model III,
which includes two descriptors, S3K and RDF045m, is
better than the other two models. The fitting power of all
the obtained models is acceptable as it satisfies the follo-
wing criteria: R2 > 0.6; F ≥ 0.70. The coefficient of deter-
mination (R2) is the amount of dependent variable varian-
ce explained by the regression mode. 
The low co-linearity of the selected molecular des-
criptors in models II and III has been verified by the low
Kxx values and ΔK ≥ 0.05. The internal predictivity of the
obtained models has been verified by cross-validation, us-
ing the Leave-One-Out (LOO) procedure. The cross-vali-
dated explained variance (Q2loo) is a measure of the vali-
dity of internal predictivity.22
The fitting concordance correlation coefficient
(CCCtr) and the LOO correlation coefficient (CCCcv) are
acceptable in all models since they are higher than 0.85,
but the highest values have been identified in model III.
RMSEtr, MAEtr, RMSEcv and MAEtr should be as low as
possible, and in model III, the values of these parameters
are lower than in the rest of the models.
Randomization testing is a technique for checking
the robustness of a QSAR model. It is expected that the
new QSAR models resulting from a Y-randomization
test should have low R2yscr and low Q
2
yscr values. This
is a strong proof that the proposed model is well-foun-
ded, rather than a result of chance correlation. Low
R2yscr and Q
2
yscr values of the reported models prove
that they were not obtained by chance correlation. 
Comparing the statistical parameters of all the re-
ported models, it is evident that model III has obtained the
best fitting and predictive power.
Model II includes the two-dimensional descriptor
(2D) F08[C-N] and the three-dimensional descriptor (3D)
Mor24p. The best model obtained (model III) was using
S3K and RDF045m, which explains 89.4% of the inhibi-
tory activity. The inhibitory activities of benzimidazole
derivatives against human DPP III have been determined
experimentally. The calculated inhibitory activities obtai-
ned using model III, the residuals, and the values of S3K
and RDF045m descriptors are given in Table 1. A scatter
plot of the experimentally obtained percentages of enzy-
me inhibition versus values calculated by model III is
shown in Fig. 1.
Two groups of clustered compounds are clearly vi-
sible in Fig. 1. Highly active compounds are clustered
into the upper right part of the graph (compounds 1, 5, 6,
2, 9), while the less active ones are clustered into the
lower left part of the graph (compounds 3, 4, 7, 11, 12,
14, 15, 16).
In order to investigate the applicability of prediction
model 3 and to detect the possible outliers, the leverage of
the training set was plotted against the residuals (Fig. 2).
As it can be seen from the plot, there are no com-
pounds outside the domain of applicability of the model,
since their leverage values are not greater than the war-
ning leverage (h* = 0.308). Moreover, no analyzed com-
pounds were considered as outliers because their standar-
dized residuals were not greater than ± 2.
Table 2. Statistical parameters of the obtained QSAR models.
Statistical 
Model I Model II Model IIIparameters
R2 0.756 0.860 0.894
R2adj 0.739 0.838 0.878
R2- R2adj 0.017 0.022 0.016
Kxx 0.000 0.212 0.344
ΔK 0.870 0.346 0.134
RMSEtr 17.510 13.283 11.553
MAEtr 13.020 11.323 10.295
CCCtr 0.861 0.925 0.944
s 18.719 14.737 12.817
F 43.459 39.855 54.780
Q2loo 0.683 0.795 0.838
RMSEcv 19.975 16.057 14.293
MAEcv 14.900 13.792 12.759
CCCcv 0.820 0.891 0.915
R2yscr 0.067 0.135 0.130
Q2yscr –0.220 –0.322 –0.329
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The best one-variable model has been obtained by
descriptor N-067, which belongs to the Ghose-Crippen
atom-centered fragments molecular descriptors.30 The
given descriptor presents a number of secondary amino
groups bonded by two aliphatic carbon or nitrogen atoms.
In the studied benzimidazole derivatives, these amino
groups are present in R substituents of compounds 3, 4, 7,
8, 11, 12, 14, 15, and 16. According to model I, an increa-
sed number of these groups in a molecule decreases the
inhibition of benzimidazoles.
The bi-parametric model II, containing the F08[C-
N] and Mor24p descriptors, gives good results in the pre-
diction of inhibitory activity. F08[C-N] belongs to the 2D
frequency fingerprint group of descriptors. F08[C-N] is
defined by the presence (1) or absence (0) of specific atom
pairs at different topological distances (from 1 to 10).31
The negative coefficient of F08[C-N] in model 2 implies
that a higher frequency of presence of C and N atoms at
the topological distance 8 decreases the inhibitory activi-
ties. The second variable in model II, Mor24p, belongs to
the 3D molecular representation of structures based on the
electron diffraction code and weighted by atomic polari-
zabilities. The descriptors reflect the three- dimensional
arrangement of atoms in a molecule and are not in correla-
tion with chemical bonds.32 Judging from the negative
coefficient of the given descriptor in model 2, an increa-
sed number of atoms with higher polarizabilities (O, N,
Cl) at the interatomic distance of 24 Å is related to weaker
inhibition.
The best multiple linear regression model, model
III, includes two descriptors, RDF045m and S3K.
RDF045m, which belongs to the RDF (Radial Distribu-
tion Function) group of descriptors, and offers informa-
tion about the three-dimensional distribution of polariza-
bilities and mass in molecules calculated at the radius of
4.5 Å from the geometrical center of each molecule.33 It is
evident from their positive coefficient in model 3 that, for
higher inhibitory activities, the benzimidazole derivatives
should have the atom mass (O, N, Cl) at the mentioned ra-
dius as a tendency. The second descriptor in model III,
S3K, is a topological descriptor that belongs to the Kier
shape indices. This group of indices is defined in terms of
the number of graph vertices (N) and the number of paths
mP with the length m (m = 1, 2, 3) in the H-depleted mole-
cular graph, and therefore encodes the information on the
centrality of branching. S3K is a Kier alpha-modified sha-
pe index that takes into consideration the contribution of
covalent radii and hybridization states (sp3) to the shape of
the molecule.34 Model III reveals that the lower value of
S3K improves the inhibition activity of compounds. The-
refore, the benzimidazole derivatives with highly branc-
hed substituents that possess sp3-hybridized nitrogen
atoms (4, 11, 12, 15), especially in combination with sp3-
hybridized oxygen atoms (3, 7, 14), have low inhibitory
activities. 
The results of QSAR analyses elucidate the reasons
of strong inhibition activity of compounds 1 and 5. Both
compounds contain two imidazolinyl groups, with only
one sp3-hybridized nitrogen atom each. Compound 5 has
slightly lower inhibition potency than compound 1 becau-
se of the presence of chloro-substituted phenyl groups in-
stead of phenyl groups on a cyclobutane ring.
3. 3. Results of the Molecular Dynamics
Simulation of the DPP III Inhibitor
Complex
In order to investigate the influence of a strong inhi-
bitor (1) on the structure of human DPP III and to better
understand the mechanism of its inhibitory activity, we
have performed a molecular modeling study. For this pur-
pose, we have prepared a model of human DPP III in com-
plex with compound 1 and performed a 40.8 ns long mo-
lecular dynamics (MD) simulation. According to the
Fig. 1. A scatter plot of experimentally obtained enzyme inhibition
percentages (% inh.exp) versus values calculated by model III (%
inh.calc).
Fig. 2. Applicability domain of the QSAR model for% inh. calcula-
ted by model III.QSAR models interpretation
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RMSD profile (Fig. 3), the protein structure stabilized af-
ter about 22 ns of MD simulation (almost immediately af-
ter the short-time heating).
Immediately after the system optimization, com-
pound 1 settled in the area of the central enzyme cleft, at
the distance of ∼ 16 Å from the catalytic Zn(II) ion (mea-
sured from the cyclobutane ring) (Fig. 4). 
Å), during the MD simulation of the complex, the Rg was
increasing during the first 20 ns. After short-time heating,
the protein domains experienced a significant shift, ac-
companied by a drastic increase in protein compactness
(the Rg decreased for about 1 Å and reached its minimum
of 26.5 Å) (Fig.5).
Fig. 3. Root Mean Square Deviations (RMSD) of the DPP III obtai-
ned during 40.8 ns of MD simulation, in complex with inhibitor 1.
Fig. 5. Protein backbone radius of gyration obtained during 40.8 ns of
productive MD simulation of DPP III in complex with the inhibitor.
Fig. 4. Surface representation of a segment of the wide DPP III
cleft, with inhibitor 1 in the optimized structure of the complex.
The Zn2+ is presented as a magenta sphere and the inhibitor is
shown in stick representation.
Fig. 6. Overlay of inhibitor 1 orientation in the DPP III binding si-
te before (orange) and after short-time heating (colored by the atom
type). The five red dotted lines represent the hydrogen bonds bet-
ween the inhibitor and the residue Ser108, Glu316, Ile386, Ala416,
and His568. Zn2+ is shown as a sphere.
In this position, the inhibitor interacts by means of
electrostatic and van der Waals forces with the residues of
the “lower” domain (residues Ser108, Phe109, Asp111,
Leu161, Tyr318, Glu327) and the “upper” domain (resi-
dues Phe556 and Arg669). However, whereas during the
simulation of ligand-free protein35 the domains progressi-
vely approached each other and the Rg decreased (the ini-
tial value was about 28.5 Å and the final one about 26.5
As a result of the domains motion, several hydrogen
bonds were formed between the inhibitor and the residue
Ser108, Glu316, Ile386, Ala416, and His565 (Fig. 6). Ap-
parently, the inhibitor reorientation sped up the protein
“closure” (Fig. S1). 
The RMSDs of the “lower” (4-335, 374-416, 670-
726) and “upper” (336-373, 417-669) protein domains
also increased during the heating period. However, du-
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ring the remaining 20 ns they remained unchanged (Fig.
S2). Apparently, during simulations at an increased tem-
perature, the protein and the ligand finely adapt to each
other.
Besides the tertiary structure changes, the protein’s
secondary structure also changed during the simulation. A
portion of α-helices reduced for ∼ 8%; however, the con-
tribution of β-sheets remained nearly unchanged during
the MD simulation (Table 3). Similar structural changes
were observed during the 101 ns long simulations of li-
gand-free human DPPIII.34
together, this could explain the experimentally observed
irreversible (tight binding) inhibition of DPP III by com-
pound 1.13
4. Conclusions
The purpose of this study was to investigate the in-
hibition effect of benzimidazole derivatives against hu-
man dipeptidyl peptidase III and to find the key features
responsible for their inhibitory activity. The results of the
QSAR analysis obtained by multiple linear regressions
showed that, for higher inhibitory activities, benzimidazo-
le derivatives should have atoms with a higher mass (O,
N, Cl) at the radius of 4.5 Å from the geometrical centers
of each molecule as a tendency. Also, an increased num-
ber of amino groups, the presence of C and N atoms at the
topological distance 8, and the highly branched substi-
tuents that possess sp3-hybridized nitrogen atoms in com-
bination with sp3-hybridized oxygen atoms, decrease the
inhibitory activities of benzimidazole derivatives. The
depicted moiety for strong inhibition activity matches the
structure of compound 1, which possesses two imidazo-
linyl and two phenyl groups as substituents. 
The importance of imidazolinyl and phenyl groups
in the mechanism of binding into the active site of human
DPP III, in one of the most potent inhibitors, compound 1,
has been confirmed by molecular dynamic simulation.
Table 3. Secondary structure elements calculated using »2Struc:
the secondary structure server« (http://2struc.cryst.bbk.ac.uk/).36
Secondary structure elements
Structure Helix (%) Sheet (%) Other (%)
After the optimization 49.0 13.4 37.6
steps
After 20 ns 45.1 13.3 41.6
After heating to 500 K 39.3 12.3 48.4
After 40.8 ns 41.4 13.0 45.6
During the MD simulation, the zinc cation, Zn2+,
was mostly six-coordinated by two histidines (His450
and His455), two glutamates (Glu451 and Glu508), and
two water molecules, as also determined for the ligand-
free DPPIII27. These results imply that the binding of in-
hibitor 1 has no significant effect on the zinc ion coordi-
nation.
An analysis of protein-ligand interactions during the
last ns of the simulation (Fig. 7) revealed that compound 1
interacted with DPP III mostly electrostatically. The
strongest interactions took place between imidazolinyl
groups and the amino acid residues of the “lower”
(Ser108, Gly110, Tyr318, and Ala416) and “upper”
(Tyr417, Asn545, and Glu667) domains. Benzimidazole
groups interacted with Tyr318 from the “lower” domain
residue and with Tyr417 from the “upper” one. The inte-
raction between the phenyl groups from compound 1 and
with Ile386, Pro387, Ala388, Phe556, Gln566, and
Met569 was a combination of van der Waals and electro-
static interactions, as well as of the cyclobutane ring and
His568.
Although the binding of compound 1 did not disturb
the coordination geometry of the catalytic zinc ion, it en-
gaged two amino acid residues (Tyr318 and His568), evo-
lutionary conserved in the M49 family, which are crucial
for the DPP III activity. Interestingly, the binding mode
and the multiple interactions established during the MD
simulations of this potent benzimidazole-based inhibitor
in complex with DPP III, differ from those established for
the reversible inhibitor Tyr-Phe-NHOH27 and the opioide
peptide tynorphin (Val-Val-Tyr-Pro-Trp)3 (see Fig.7. and
compare with the Supplemental Fig. S3 and Fig. S4). Al-
Fig. 7. Orientation and interactions of inhibitor 1 in complex with
human DPP III obtained after 40.8 ns of MD simulations. The zinc
cation is shown as a magenta sphere, the inhibitor in ball-and-stick,
and the amino acid residues in stick representation.
877Acta Chim. Slov. 2015, 62, 867–878
Rastija et al.:  Synthesis, QSAR, and molecular dynamics simulation   ...
Most of the interactions of imidazolinyl groups were ac-
hieved by electrostatic forces with the residuals Ser108,
Gly110, Tyr318, and Ala416 of the “lower” domain, and
with the residuals Tyr417, Asn545, and Glu667 of the
“upper” domain of enzymes, while benzimidazole groups
were less relevant for the interactions. The phenyl groups
of compound 1 interacted mainly by means of van der
Waals and electrostatic forces with the residuals Ile386,
Pro387, Ala388, Phe556, Gln566, and Met569, as well as
the cyclobutane ring with His568. The results of MD also
imply that the binding of compound 1 has no important
effect on the coordination geometry of the catalytic zinc
ion.
The present study can guide the rational synthesis of
novel inhibitors with an increased affinity and efficacy of
inhibition in DPP III.
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Povzetek
[tudija molekularnega modeliranja je bila izvedena na 16 inhibitorjih na osnovi benzimidazola, ki inhibirajo ~love{ko
dipeptidil peptidazo III (DPP III). Osem od teh so nove spojine, sintetizirane z odli~nimi izkoristki in uporabo zelenih
pristopov kemije .Namen te {tudije je pojasnjevanje strukturnih zna~ilnosti derivatov benzimidazola, potrebnih za anta-
gonizem delovanja ~love{kega DPP III, ob uporabi analize povezave med strukturo in aktivnostjo (QSAR). Da bi razu-
meli mehanizme, kako se tovrstni mo~ni inhibitorji ve`ejo v aktivno mesto encima, smo uporabili simulacijske metode
molekularne dinamike (MD). Najbolj{i model vklju~uje S3K in RDF045m deskriptorje, ki razlo`ijo 89,4 % zaviralnega
delovanja . Opisani del z mo~no aktivnostjo inhibicije se ujema s strukturo najmo~nej{e spojine. MD simulacija je
pokazala pomen imidazolinih in fenilnih skupin v mehanizmu vezavev aktivno mesto ~love{kega DPP III.
